Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
2001 1
2003 1
2006 1
2008 5
2009 3
2010 3
2011 4
2012 1
2013 8
2014 4
2015 10
2016 4
2017 10
2018 7
2019 6
2020 1
2021 4
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group. McInnes IB, et al. Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13. Lancet. 2013. PMID: 23769296 Clinical Trial.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Leonardi CL, et al. Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4. Lancet. 2008. PMID: 18486739 Clinical Trial.
Practical aspects of prescribing a biologic.
Poulin Y, Bourcier M. Poulin Y, et al. Among authors: bourcier m. J Cutan Med Surg. 2009 Sep-Oct;13 Suppl 2:S93-S101. doi: 10.2310/7750.2009.00026. J Cutan Med Surg. 2009. PMID: 19799832 Review.
An Open Letter to Health Canada.
Papp K, Albrecht L, Barber K, Bourcier M, Dion PL, Freiman A, Gooderham M, Guenther L, Gulliver W, Hong CH, Lynde C, Poulin Y, Siddha S, Toole J, Toth D, Vender R, Wasel N, Wiseman M. Papp K, et al. Among authors: bourcier m. J Cutan Med Surg. 2017 May/Jun;21(3):195-196. doi: 10.1177/1203475417704642. J Cutan Med Surg. 2017. PMID: 28903599 No abstract available.
Management of malignant melanoma: best practices.
Smylie M, Claveau J, Alanen K, Taillefer R, George R, Wong R, Mason WP; Canadian Expert Panel on Malignant Melanoma. Smylie M, et al. J Cutan Med Surg. 2009 Mar-Apr;13(2):55-73. doi: 10.2310/7750.2008.08029. J Cutan Med Surg. 2009. PMID: 19459245 Review.
69 results